Medicare widens drugs it accepts for cancer care
New York Times, January 27, 2009
Medicare has expanded its coverage of drugs for cancer treatments not approved by the Food and Drug Administration. Cancer doctors had clamored for the changes, saying that some of these treatments were essential if patients were to receive the most up-to-date care. But for many such uses there is scant clinical evidence that the drugs are effective, despite costing as much as $10,000 a month. The new Medicare rules are the latest twist in a protracted debate over federal spending on drugs prescribed for uses other than those for which they have been specifically approved.
- mHealth Tackles Readmissions
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Sharp HealthCare Leaves Pioneer ACO Program
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Proton Beam Therapy Poised for Growth in US
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013